NASDAQ:HUMAW
Humacyte, Inc.
- Stock
Last Close
6.47
16/05 20:00
Market Cap
301.40M
Beta: -
Volume Today
4.32M
Avg: -
PE Ratio
−3.64
PFCF: −4.65
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | ||
|---|---|---|---|---|---|---|
average inventory | -15.50K - | -15.50K 0% | ||||
average payables | 2.18M - | 1.84M 15.54% | 4.04M 119.17% | |||
average receivables | 144.50K - | 103.50K 28.37% | 15.50K 85.02% | |||
book value per share | -3.40 - | 3.06 189.87% | 1.13 62.88% | 0.13 88.46% | ||
capex per share | -2.81 - | -0.00 99.89% | -0.01 78.28% | -0.01 84.77% | ||
capex to depreciation | -1.73 - | -0.04 97.80% | -0.03 29.89% | -0.13 378.16% | ||
capex to operating cash flow | 0.11 - | 0.01 94.94% | 0.00 52.65% | 0.01 443.74% | ||
capex to revenue | -1.31 - | |||||
cash per share | 0.39 - | 5.64 1,355.38% | 1.47 73.88% | 0.78 47.22% | ||
days of inventory on hand | ||||||
days payables outstanding | 15.60K - | |||||
days sales outstanding | ||||||
debt to assets | 0.27 - | 0.18 34.85% | 0.23 32.65% | |||
debt to equity | -0.08 - | 0.41 601.68% | 0.41 1.17% | |||
dividend yield | ||||||
earnings yield | -0.07 - | 0.13 297.43% | 0.30 128.01% | -0.38 227.70% | ||
enterprise value | 1.04B - | 120.75M 88.35% | 115.43M 4.41% | 229.56M 98.88% | ||
enterprise value over ebitda | -18.52 - | -0.88 95.24% | -0.72 18.34% | -2.29 218.74% | ||
ev to operating cash flow | -18.65 - | -1.49 92.03% | -1.62 9.11% | |||
ev to sales | ||||||
free cash flow per share | -27.67 - | -0.54 98.04% | -2.04 275.39% | -0.70 65.61% | ||
free cash flow yield | -2.86 - | -0.05 98.14% | -0.28 426.59% | -0.33 18.16% | ||
graham net net | -4.05 - | 1.53 137.87% | 0.63 59.16% | -0.33 152.87% | ||
graham number | 7.15 - | 8.04 12.47% | 3.99 50.37% | 1.78 55.46% | ||
income quality | 0.84 - | 3.07 267.10% | 5.94 93.87% | |||
intangibles to total assets | 0 - | 0 | 0 | 0 | 0 | |
interest coverage | -37.29 - | -29.34 21.33% | -18.68 36.34% | -13.64 26.96% | ||
interest debt per share | 0.30 - | 1.37 354.99% | 0.52 61.84% | |||
inventory turnover | ||||||
invested capital | -0.08 - | 0.41 601.68% | 0.41 1.17% | |||
market cap | 27.93M - | 1.05B 3,650.56% | 289.79M 72.34% | 217.44M 24.97% | 293.71M 35.08% | |
net current asset value | -415.56M - | 64.98M 115.64% | 66.83M 2.85% | -31.40M 146.98% | ||
net debt to ebitda | 0.20 - | 1.23 524.03% | 0.64 48.44% | 0.64 0.79% | ||
net income per share | -0.67 - | 0.94 240.75% | 0.62 33.64% | -1.07 271.88% | ||
operating cash flow per share | -24.85 - | -0.54 97.83% | -2.03 276.52% | -0.69 66.02% | ||
payables turnover | 0.02 - | |||||
receivables turnover | ||||||
research and ddevelopement to revenue | 12.22 - | |||||
return on tangible assets | -0.64 - | 0.13 120.34% | 0.31 139.95% | -0.86 374.85% | ||
revenue per share | 2.14 - | |||||
roe | 0.20 - | 0.31 56.61% | 0.55 78.76% | -8.18 1,588.98% | ||
roic | 0.23 - | 0.59 163.39% | 2.47 316.30% | -3.35 235.56% | ||
sales general and administrative to revenue | 2.63 - | |||||
shareholders equity per share | -3.40 - | 3.06 189.87% | 1.13 62.88% | 0.13 88.46% | ||
stock based compensation to revenue | 0.72 - | |||||
tangible asset value | -350.32M - | 122.17M 134.88% | 116.93M 4.29% | 13.55M 88.42% | ||
tangible book value per share | -3.40 - | 3.06 189.87% | 1.13 62.88% | 0.13 88.46% | ||
working capital | 30.22M - | 218.29M 622.43% | 134.63M 38.33% | 64.83M 51.84% |
All numbers in USD (except ratios and percentages)